Drugs / D660
last change May 2024 re-read 2 minutes ago

D660

Developed for
essential hypertension
Investigated by
Chong Kun Dang Pharmaceutical

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05931224 Jun 2023 → May 2024 essential hypertension Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as D660 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05931224